Pharmaceutical intermediates
Sunitinib Malate Intermediates
2 pharmaceutical intermediates for Sunitinib Malate. Indication: Pancreatic neuroendocrine tumors; Renal cell carcinoma; Gastrointestinal stromal tumor.
About Sunitinib Malate
- Originator
- Pfizer Inc
- Indication
- Pancreatic neuroendocrine tumors; Renal cell carcinoma; Gastrointestinal stromal tumor
- Approved Date
- 03/31/2009
Available intermediates
2 intermediates currently listed for Sunitinib Malate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Fluoro-2-oxindole | 56341-41-4 | / | / |
| 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid | 253870-02-9 | / | / |
Building toward Sunitinib Malate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →